Association Between the Albumin-Bilirubin (ALBI) Score and All-cause Mortality Risk in Intensive Care Unit Patients with Heart Failure

Overview

Journal Glob Heart

Publisher Ubiquity Press

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 23

PMID 39713194

Authors

Jiuyi Wang

Kai Wang

Guibo Feng

Xin Tian

Affiliations

Soon will be listed here.

Abstract

Background: The albumin-bilirubin (ALBI) score has demonstrated prognostic value in a range for liver and heart diseases. However, its association with all-cause mortality in intensive care unit (ICU) patients with heart failure remains uncertain.

Objective: This study sought to investigate the relationship between the ALBI score and the risk of all-cause mortality in ICU patients with heart failure.

Methods And Results: The ICU patients diagnosed with heart failure were selected from the Medical Information Mart for Intensive Care IV database (MIMIC-IV, version 2.2) and stratified into tertiles according to their ALBI scores. The primary outcome of interest was the occurrence of all-cause mortality within 365 days post-discharge. The analysis encompassed a cohort of 4,239 patients, with Kaplan-Meier curves indicating that individuals with higher ALBI levels exhibited an elevated risk of all-cause mortality (log-rank p < 0.001). Multivariate adjusted Cox regression and subgroup analysis demonstrated that individuals in T2 (hazard ratio (HR) 1.09, 95% CI 0.99-1.21) and T3 (HR 1.17, 95% CI 1.02-1.34) had an increased risk of mortality compared to individuals in T1 (p for trend < 0.001), and each incremental tertile in ALBI was linked to a 10% rise in mortality risk, while each individual unit increase in ALBI was associated with a 36% increase in mortality risk. This relationship was consistently observed across most subgroups, except for using or not using inotropes or vasopressors, different ages, different creatinine levels. The restricted cubic spline (RCS) analysis indicated a linear relationship between ALBI levels and the risk of all-cause mortality.

Conclusion: The ALBI scores are independently associated with the risk of all-cause mortality in ICU patients with heart failure, particularly in those not using inotropes or vasopressors, younger patients, and with lower levels of creatinine. ALBI may help identify high-risk patients and optimize risk stratification in this population.

References

Luo Y, Li Z, Liu J, Chong Y, Wu B . Prognostic value of the albumin-bilirubin score in critically ill patients with heart failure. Ann Palliat Med. 2022; 10(12):12727-12741. DOI: 10.21037/apm-21-3424. View

Maack C, Eschenhagen T, Hamdani N, Heinzel F, Lyon A, Manstein D . Treatments targeting inotropy. Eur Heart J. 2018; 40(44):3626-3644. PMC: 7963133. DOI: 10.1093/eurheartj/ehy600. View

Allen L, Felker G, Pocock S, McMurray J, Pfeffer M, Swedberg K . Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009; 11(2):170-7. PMC: 2639422. DOI: 10.1093/eurjhf/hfn031. View

Johnson A, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S . MIMIC-IV, a freely accessible electronic health record dataset. Sci Data. 2023; 10(1):1. PMC: 9810617. DOI: 10.1038/s41597-022-01899-x. View

El Hadi H, Di Vincenzo A, Vettor R, Rossato M . Relationship between Heart Disease and Liver Disease: A Two-Way Street. Cells. 2020; 9(3). PMC: 7140474. DOI: 10.3390/cells9030567. View

Harjola V, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca H, Chioncel O . Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017; 19(7):821-836. PMC: 5734941. DOI: 10.1002/ejhf.872. View

Han S, Wang C, Tong F, Li Y, Li Z, Sun Z . Prognostic impact of albumin-bilirubin score on the prediction of in-hospital mortality in patients with heart failure: a retrospective cohort study. BMJ Open. 2022; 12(1):e049325. PMC: 8728421. DOI: 10.1136/bmjopen-2021-049325. View

Duman Z, Timur B . Albumin-Bilirubin Score: A Novel Mortality Predictor in Valvular Surgery. Braz J Cardiovasc Surg. 2022; 38(2):271-277. PMC: 10069255. DOI: 10.21470/1678-9741-2022-0008. View

Moller S, Bernardi M . Interactions of the heart and the liver. Eur Heart J. 2013; 34(36):2804-11. DOI: 10.1093/eurheartj/eht246. View

10.

Jiang M, Wei X, Huang J, Su Z, Lin Y, Yu D . Albumin-Bilirubin Score to Predict Outcomes in Patients with Idiopathic Dilated Cardiomyopathy. Arq Bras Cardiol. 2022; 118(6):1108-1115. PMC: 9345152. DOI: 10.36660/abc.20210035. View

11.

Kudo M . Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma. Liver Cancer. 2022; 11(1):1-8. PMC: 8820154. DOI: 10.1159/000521374. View

12.

Dries D, Exner D, Domanski M, Greenberg B, Stevenson L . The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000; 35(3):681-9. DOI: 10.1016/s0735-1097(99)00608-7. View

13.

Tromp J, Paniagua S, Lau E, Allen N, Blaha M, Gansevoort R . Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ. 2021; 372:n461. PMC: 7986583. DOI: 10.1136/bmj.n461. View

14.

Foroutan F, Rayner D, Ross H, Ehler T, Srivastava A, Shin S . Global Comparison of Readmission Rates for Patients With Heart Failure. J Am Coll Cardiol. 2023; 82(5):430-444. DOI: 10.1016/j.jacc.2023.05.040. View

15.

Qiao P, Li L, Ruan H, Zhang M, Wang Z, Li X . Application of the ALBI Scoring System for Mortality Outcome Prediction in Patients with Hypertrophic Cardiomyopathy. Glob Heart. 2022; 17(1):73. PMC: 9562974. DOI: 10.5334/gh.1163. View

16.

Ahmad T, Miller P, McCullough M, Desai N, Riello R, Psotka M . Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail. 2019; 21(9):1064-1078. PMC: 6774302. DOI: 10.1002/ejhf.1557. View

17.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves H . Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014; 33(6):550-8. PMC: 4322258. DOI: 10.1200/JCO.2014.57.9151. View

18.

Tian B, Yan L, Ding Z, Liu H, Han C, Meng G . Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis. Int Immunopharmacol. 2022; 114:109519. DOI: 10.1016/j.intimp.2022.109519. View

19.

Yamashita Y, Umemura T, Kimura T, Joshita S, Hirohara J, Nakano T . Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis. JHEP Rep. 2023; 5(4):100662. PMC: 9976453. DOI: 10.1016/j.jhepr.2022.100662. View

20.

Simonetto D, Gines P, Kamath P . Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020; 370:m2687. DOI: 10.1136/bmj.m2687. View